Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer

References

• Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–8. doi:10.1016/s0022-5347(17)58737-6.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–58. doi:10.4049/jimmunol.1490019.
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005:CD001425. doi:10.1002/14651858.CD001425.pub2.
   PubMedGoogle Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82. doi:10.1200/JCO.2014.59.4358.
   PubMed Web of Science ®Google Scholar
• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35. doi:10.1016/j.coi.2015.01.006.
   PubMed Web of Science ®Google Scholar
• Cui L. Rating health web sites using the principles of citation analysis: a bibliometric approach. J Med Internet Res. 1999;1:E4. doi:10.2196/jmir.1.1.e4.
   PubMed Web of Science ®Google Scholar
• Jia Z, Ding F, Wu Y, He Q, Ruan D. The 50 most-cited articles in orthopaedic surgery from mainland China. Clin Orthop Relat Res. 2015;473(7):2423–30. doi:10.1007/s11999-015-4132-1.
   PubMed Web of Science ®Google Scholar
• Gisvold SE. Citation analysis and journal impact factors–is the tail wagging the dog? Acta Anaesthesiol Scand. 1999;43:971–73. doi:10.1034/j.1399-6576.1999.431001.x.
   PubMed Web of Science ®Google Scholar
• He L, Fang H, Wang X, Wang Y, Ge H, Li C, Chen C, Wan Y, He H . The 100 most-cited articles in urological surgery: a bibliometric analysis. Int J Surg. 2020;75:74–79. doi:10.1016/j.ijsu.2019.12.030.
   PubMed Web of Science ®Google Scholar
• He L, Fang H, Chen C, Wu Y, Wang Y, Ge H, Wang L, Wan Y, He H. Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis. Medicine (Baltimore). 2020;99:e19760. doi:10.1097/MD.0000000000019760.
   PubMed Web of Science ®Google Scholar
• Bao G, Pan L, Fang H, Wu X, Yu H, Cai S, Yu B, Wan Y. Academic review and perspectives on robotic exoskeletons. IEEE Trans Neural Syst Rehabil Eng. 2019;27(11):2294–304. doi:10.1109/TNSRE.2019.2944655.
   PubMed Web of Science ®Google Scholar
• Essential Science Indicators.
   Google Scholar
• Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FCD, Oosterlinck W, Prescott S, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin. Eur Urol. 2016;69:60–69. doi:10.1016/j.eururo.2015.06.045.
   PubMed Web of Science ®Google Scholar
• Hasanov E, Gao J, Tannir NM. The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results. Cancer J. 2020;26:419–31. doi:10.1097/PPO.0000000000000471.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520–26. doi:10.1158/1078-0432.CCR-10-3126.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86–91. discussion 91-82. doi:10.1097/01.ju.0000162059.64886.1c.
   PubMed Web of Science ®Google Scholar
• Connelly TM, Malik Z, Sehgal R, Byrnes G, Coffey JC, Peirce C. The 100 most influential manuscripts in robotic surgery: a bibliometric analysis. J Robot Surg. 2019;14:155–65. doi:10.1007/s11701-019-00956-9.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Yoon DY, Kim ES, Lee K, Bae JS, Lee J-H. The 100 most-cited articles in neuroimaging: a bibliometric analysis. Neuroimage. 2016;139:149–56. doi:10.1016/j.neuroimage.2016.06.029.
   PubMed Web of Science ®Google Scholar
• Mehta G, Hopf H, Krief A, Matlin SA. Realigning science, society and policy in uncertain times. R Soc Open Sci. 2020;7(5):200554. doi:10.1098/rsos.200554.
   PubMed Web of Science ®Google Scholar
• Hofman K, Kramer B. Human resources for research: building bridges through the Diaspora. Glob Health Action. 2015;8:29559. doi:10.3402/gha.v8.29559.
   PubMed Web of Science ®Google Scholar
• Califf RM. The US food and drug administration and cardiovascular medicine: reflections and observations. Circulation. 2016;134:501–03. doi:10.1161/CIRCULATIONAHA.116.022137.
   PubMed Web of Science ®Google Scholar
• Frich JC, Brewster AL, Cherlin EJ, Bradley EH. Leadership development programs for physicians: a systematic review. J Gen Intern Med. 2015;30(5):656–74. doi:10.1007/s11606-014-3141-1.
   PubMed Web of Science ®Google Scholar
• Anderson G, Metcalfe A. Calling for international collaborative research in nursing, genetics and genomics: a discussion paper. Int J Nurs Stud. 2008;45:323–28. doi:10.1016/j.ijnurstu.2006.08.013.
   PubMed Web of Science ®Google Scholar
• Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–93. doi:10.1038/nri2817.
   PubMed Web of Science ®Google Scholar
• Fay EK, Graff JN. Immunotherapy in prostate cancer. Cancers (Basel). 2020:12. doi:10.3390/cancers12071752.
   Google Scholar
• Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674–82. doi:10.1158/1078-0432.CCR-07-5212.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides SN, Lee JL, Sarwar N, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–94. doi:10.1056/NEJMoa2106391.
   PubMed Web of Science ®Google Scholar
• Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919–30. doi:10.1016/S1470-2045(21)00147-9.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee JL, Bjarnason GA, Larkin JMG, Gafanov RA, Kochenderfer MD, Jensen NV, Donskov F, Malik J, Poprach A, et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol. 2021;39:1020–28. doi:10.1200/JCO.20.02363.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39:1029–39. doi:10.1200/JCO.20.02365.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525–37. doi:10.1016/S1470-2045(21)00004-8.
   PubMed Web of Science ®Google Scholar
• Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. Immune-checkpoint blockade enhances 225 Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med. 2021;62(2):228–31. doi:10.2967/jnumed.120.246041.
   PubMed Web of Science ®Google Scholar
• Sharma M, Khong H, Fa’ak F, Bentebibel S-E, Janssen LME, Chesson BC, Creasy CA, Forget M-A, Kahn LMS, Pazdrak B, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020;11(1):661. doi:10.1038/s41467-020-14471-1.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347–362 e324. doi:10.1016/j.cell.2020.08.053.
   PubMed Web of Science ®Google Scholar
• Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11(4):838–57. doi:10.1158/2159-8290.CD-20-1680.
   PubMed Web of Science ®Google Scholar
• Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021;11(7):3089–108. doi:10.7150/thno.53649.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82. doi:10.1016/j.eururo.2020.09.046.
   PubMed Web of Science ®Google Scholar
• Pan RY, Chung WH, Chu MT, Chen S-J, Chen H-C, Zheng L, Hung S-I. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874. doi:10.1155/2018/4325874.
   PubMed Web of Science ®Google Scholar
• Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238–46. doi:10.7150/thno.24387.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhao X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biol Med. 2021;18(2):352–71. doi:10.20892/j.2095-3941.2021.0004.
   PubMed Web of Science ®Google Scholar
• Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at Dawn. Cancer Sci. 2016;107:1373–79. doi:10.1111/cas.13027.
   PubMed Web of Science ®Google Scholar
• Ramos MB, Koterba E, Rosi Junior J, Teixeira MJ, Figueiredo EG. A bibliometric analysis of the most cited articles in neurocritical care research. Neurocrit Care. 2019;31:365–72. doi:10.1007/s12028-019-00731-6.
   PubMed Web of Science ®Google Scholar